Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
RET (Ret Proto-Oncogene)
i
Other names:
RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5979
Related tests:
‹
FoundationOne® CDx (110)
Guardant360® CDx (54)
Oncomine™ Dx Target Test (10)
OncoDEEP (3)
TruSight Oncology 500 Assay (3)
Guardant360 TissueNext™ (2)
Oncomine™ Comprehensive Assay v3M (2)
AmoyDx® Pan Lung Cancer PCR Panel (1)
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)
Idylla™ GeneFusion Assay (1)
InVisionFirst®-Lung (1)
ACTOnco
ASPYRE-Lung
AVENIO Tumor Tissue Expanded Kit
AVENIO Tumor Tissue Surveillance Kit
AVENIO Tumor Tissue Targeted Kit
AVENIO ctDNA Expanded Kit
AVENIO ctDNA Surveillance Kit
AVENIO ctDNA Targeted Kit
AmoyDx® Essential NGS Panel
AmoyDx® HANDLE Classic NGS Panel
AnchorAIM® 10 Gene Test for Individualized Treatment of Lung Cancer
AnchorAIM® 72 gene detection for individualized treatment of solid tumors
Archer® FusionPlex® Lung Kit
Archer® FusionPlex® Oncology Research Kit
Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit
Archer® VariantPlex® Solid Tumor Kit
Archer™ FusionPlex™ Core Solid Tumor Panel
BROCA Cancer Risk Panel
Blueprint Genetics Comprehensive Hereditary Cancer Panel
CancerNext-Expanded®
CustomNext-Cancer®
Find It®
Follow It®
FusionPlex® Dx
FusionPlex® Pan Solid Tumor v2 panel
GeneStrat® test
HDPCR NSCLC RUO Assay
HTG EdgeSeq Lung Fusions Assay
Labcorp® Plasma Focus™
Liquid Biopsy Solid Tumor
Liquid Trace™ Solid Tumor
LiquidGx™
LiquidHALLMARK®
LiquidPlex™
LungCure™ CDx
NGS Targeted Hotspot Panel
NeXT Dx™ Test
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
Northstar Select™
NovoFocus™ NSCLC 2.0 Test
OncoGuide™ NCC Oncopanel System
OncoKey™ SL 60 Plus Assay
OncoPanel™ Assay
OncoPlus
OncoScreen™ Focus CDx Tissue Kit
Oncomine Dx Express Test
Oncomine Focus Assay
Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
Oncomine Precision Assay
Oncomine Tumor Mutation Load Assay
Oncomine™ Comprehensive Assay Plus
Oncotype MAP™ Pan-Cancer Tissue Test
OptiSeq™ Lung Cancer Panel
OptiSeq™ Pan-Cancer Gene Panel
PGDx elio™ plasma resolve assay
PGDx elio™ tissue complete assay
PGLNext®
PredicineCARE™
Resolution ctDx Lung Assay™
SOPHiA DDM Dx RNAtarget Oncology Solution
SOPHiA DDM™ Solid Tumor Plus Solution
Target Selector™ NGS Lung Panel
Tempus xF Assay
Tempus xF+ Panel
Tempus xG+
Theralink Assay
ThyGeNEXT® + ThyraMIR®
TruSight Oncology Comprehensive (EU)
TruSight Tumor 15 Assay
TruSight Tumor 170 Assay
VarMap™ Pan-Cancer NGS Panel
oncoReveal™ Core LBx
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
oncoReveal™ Solid Tumor v2 Panel
FoundationOne® CDx (110)
Guardant360® CDx (54)
Oncomine™ Dx Target Test (10)
OncoDEEP (3)
TruSight Oncology 500 Assay (3)
Guardant360 TissueNext™ (2)
Oncomine™ Comprehensive Assay v3M (2)
AmoyDx® Pan Lung Cancer PCR Panel (1)
Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)
Idylla™ GeneFusion Assay (1)
InVisionFirst®-Lung (1)
ACTOnco
ASPYRE-Lung
AVENIO Tumor Tissue Expanded Kit
AVENIO Tumor Tissue Surveillance Kit
AVENIO Tumor Tissue Targeted Kit
AVENIO ctDNA Expanded Kit
AVENIO ctDNA Surveillance Kit
AVENIO ctDNA Targeted Kit
AmoyDx® Essential NGS Panel
AmoyDx® HANDLE Classic NGS Panel
AnchorAIM® 10 Gene Test for Individualized Treatment of Lung Cancer
AnchorAIM® 72 gene detection for individualized treatment of solid tumors
Archer® FusionPlex® Lung Kit
Archer® FusionPlex® Oncology Research Kit
Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit
Archer® VariantPlex® Solid Tumor Kit
Archer™ FusionPlex™ Core Solid Tumor Panel
BROCA Cancer Risk Panel
Blueprint Genetics Comprehensive Hereditary Cancer Panel
CancerNext-Expanded®
CustomNext-Cancer®
Find It®
Follow It®
FusionPlex® Dx
FusionPlex® Pan Solid Tumor v2 panel
GeneStrat® test
HDPCR NSCLC RUO Assay
HTG EdgeSeq Lung Fusions Assay
Labcorp® Plasma Focus™
Liquid Biopsy Solid Tumor
Liquid Trace™ Solid Tumor
LiquidGx™
LiquidHALLMARK®
LiquidPlex™
LungCure™ CDx
NGS Targeted Hotspot Panel
NeXT Dx™ Test
NeoLAB® Solid Tumor Liquid Biopsy
NeoTYPE® Lung Tumor Profile
Northstar Select™
NovoFocus™ NSCLC 2.0 Test
OncoGuide™ NCC Oncopanel System
OncoKey™ SL 60 Plus Assay
OncoPanel™ Assay
OncoPlus
OncoScreen™ Focus CDx Tissue Kit
Oncomine Dx Express Test
Oncomine Focus Assay
Oncomine Lung Cell-Free Total Nucleic Acid Research Assay
Oncomine Precision Assay
Oncomine Tumor Mutation Load Assay
Oncomine™ Comprehensive Assay Plus
Oncotype MAP™ Pan-Cancer Tissue Test
OptiSeq™ Lung Cancer Panel
OptiSeq™ Pan-Cancer Gene Panel
PGDx elio™ plasma resolve assay
PGDx elio™ tissue complete assay
PGLNext®
PredicineCARE™
Resolution ctDx Lung Assay™
SOPHiA DDM Dx RNAtarget Oncology Solution
SOPHiA DDM™ Solid Tumor Plus Solution
Target Selector™ NGS Lung Panel
Tempus xF Assay
Tempus xF+ Panel
Tempus xG+
Theralink Assay
ThyGeNEXT® + ThyraMIR®
TruSight Oncology Comprehensive (EU)
TruSight Tumor 15 Assay
TruSight Tumor 170 Assay
VarMap™ Pan-Cancer NGS Panel
oncoReveal™ Core LBx
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
oncoReveal™ Solid Tumor v2 Panel
›
Associations
(253)
News
Trials
VERI cancer hierarchy
Reset Filters
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
EP0031
Sensitive: B - Late Trials
Drug Discovery News - 3 weeks (New B)
EP0031
Sensitive
:
B
Drug Discovery News - 3wk
EP0031
Sensitive: B - Late Trials
Drug Discovery News - 3 weeks
EP0031
Sensitive
:
B
Drug Discovery News - 3 weeks - (New B)
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
RET fusion
Solid Tumor
RET fusion
Solid Tumor
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Follicular Carcinoma
RET fusion
Thyroid Gland Follicular Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
cabozantinib tablet
Sensitive: A2 - Guideline
cabozantinib tablet
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET mutation
Thyroid Gland Anaplastic Carcinoma
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET M918T
Thyroid Gland Medullary Carcinoma
RET M918T
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
cabozantinib capsule
Sensitive: A2 - Guideline
cabozantinib capsule
Sensitive
:
A2
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
vandetanib
Sensitive: A2 - Guideline
vandetanib
Sensitive
:
A2
vandetanib
Sensitive: A2 - Guideline
vandetanib
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Follicular Carcinoma
RET fusion
Thyroid Gland Follicular Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Anaplastic Carcinoma
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Neuroendocrine Tumor
RET fusion
Neuroendocrine Tumor
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Ovarian Cancer
RET fusion
Ovarian Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Salivary Gland Cancer
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Colon Cancer
RET fusion
Colon Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Biliary Tract Cancer
RET fusion
Biliary Tract Cancer
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Hepatocellular Cancer
RET fusion
Hepatocellular Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Colorectal Cancer
RET fusion
Colorectal Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Pancreatic Adenocarcinoma
RET fusion
Pancreatic Adenocarcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Biliary Tract Cancer
RET fusion
Biliary Tract Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Peritoneal Cancer
RET fusion
Peritoneal Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Fallopian Tube Cancer
RET fusion
Fallopian Tube Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Cervical Cancer
RET fusion
Cervical Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login